123 related articles for article (PubMed ID: 19151659)
1. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study.
Birnbaum F; Mayweg S; Reis A; Böhringer D; Seitz B; Engelmann K; Messmer EM; Reinhard T
Eye (Lond); 2009 Nov; 23(11):2063-70. PubMed ID: 19151659
[TBL] [Abstract][Full Text] [Related]
2. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.
Reinhard T; Reis A; Böhringer D; Malinowski M; Voiculescu A; Heering P; Godehardt E; Sunmacher R
Graefes Arch Clin Exp Ophthalmol; 2001 Jun; 239(5):367-72. PubMed ID: 11482341
[TBL] [Abstract][Full Text] [Related]
3. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.
Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197
[TBL] [Abstract][Full Text] [Related]
4. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study.
Reinhard T; Mayweg S; Sokolovska Y; Seitz B; Mittelviefhaus H; Engelmann K; Voiculescu A; Godehardt E; Sundmacher R
Transpl Int; 2005 Jun; 18(6):703-8. PubMed ID: 15910297
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.
Birnbaum F; Böhringer D; Sokolovska Y; Sundmacher R; Reinhard T
Transplantation; 2005 Apr; 79(8):964-8. PubMed ID: 15849551
[TBL] [Abstract][Full Text] [Related]
6. An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty.
Birnbaum F; Reis A; Böhringer D; Sokolowska Y; Mayer K; Voiculescu A; Oellerich M; Sundmacher R; Reinhard T
Transplantation; 2006 Mar; 81(5):767-72. PubMed ID: 16534481
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study.
Mayer K; Reinhard T; Reis A; Voiculescu A; Sundmacher R
Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):1051-4. PubMed ID: 12928902
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial.
Reis A; Reinhard T; Voiculescu A; Kutkuhn B; Godehardt E; Spelsberg H; Althaus C; Sundmacher R
Br J Ophthalmol; 1999 Nov; 83(11):1268-71. PubMed ID: 10535855
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression.
Chow SP; Cook SD; Tole DM
Cornea; 2015 Nov; 34(11):1395-9. PubMed ID: 26382894
[TBL] [Abstract][Full Text] [Related]
10. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model.
Birnbaum F; Schwartzkopff J; Scholz C; Reis A; Reinhard T
Eye (Lond); 2007 Dec; 21(12):1516-23. PubMed ID: 17401326
[TBL] [Abstract][Full Text] [Related]
11. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk.
Chatel MA; Larkin DF
Am J Ophthalmol; 2010 Aug; 150(2):179-84. PubMed ID: 20570235
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Transplantation; 1998 Jan; 65(2):235-41. PubMed ID: 9458021
[TBL] [Abstract][Full Text] [Related]
16. [Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study].
Reinhard T; Reis A; Kutkuhn B; Voiculescu A; Sundmacher R
Klin Monbl Augenheilkd; 1999 Sep; 215(3):201-2. PubMed ID: 10528287
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study.
Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P;
J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338
[TBL] [Abstract][Full Text] [Related]
18. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
19. Experimental efficacy of mycophenolate mofetil implant on high-risk corneal allograft rejection and its biocompatibility in the anterior chamber of rabbits.
Xin M; Wang T; Shi W; Wu X
J Ocul Pharmacol Ther; 2012 Dec; 28(6):609-17. PubMed ID: 22846154
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis.
Maier AK; Ozlügedik S; Rottler J; Heussen FM; Klamann MK; Huber KK; Joussen AM; Winterhalter S
Cornea; 2011 Dec; 30(12):1398-405. PubMed ID: 21996945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
